Promoting the application of carbon -14 isotopes in innovative pharmaceutical development and other fields, "Beta Pharmaceuticals" completed tens of millions of yuan in round B financing.

Release time:

2022-10-28

It is reported that "Beta Pharmaceuticals" has recently completed tens of millions of yuan in round B financing on March 20, 2021. This round of financing is led by Dongfang Huifu Investment Holdings Co., Ltd. The funds raised will be mainly used for technological research in the field of carbon -14(C14), new product development, industrialization construction, and localization and internationalization of existing marking technology.

"Beta Pharmaceuticals" was established in November 2008, is a pharmaceutical technology company, specializing in the development of C- 14 and other radioactive isotope labeled precursor compounds, and the pharmaceutical, pesticide small molecules or bioactive molecules are labeled, so as to carry out drug generation, clinical, environmental and disease detection research. The Company's principal activities include the development of C- 14 radioisotope labeled precursor compounds and C- 14 labeling services; the development of urea-14C for gastric Helicobacter pylori diagnostics; and the development of GMP grade urea-13C for gastric Helicobacter pylori diagnostics.

According to the company's official website and the head of the Leopard Research Institute, radioisotope C- 14 labeled organic matter is a tracer necessary to study the movement and change of corresponding non-labeled substances in complex systems (humans, animals, plants, microorganisms, soil, water, etc.). Carbon atom is the basic element to form the skeleton of organic compounds, and the use of radioactive isotope C- 14 to label organic matter is the most basic and most commonly used way of labeling organic matter; compared with radioactive element tritium, its stability is better. At present, C- 14 markers are widely used in innovative pharmaceutical development, pesticide research, biotechnology and medical testing. Isotope C- 13 is also an excellent tracer material with stable chemical properties and no radioactivity. Its largest market demand is in high-tech fields such as medical diagnosis and biomedicine. At present, isotope C- 13 in China is mainly used in C- 13 breath test, which is the "gold standard" for clinical detection of Helicobacter pylori and is suitable for early diagnosis of common digestive system diseases such as stomach, liver and intestinal tract. With the gradual popularization of the clinical application of C- 13 breath testing, the demand for isotope C- 13 in China is growing rapidly every year.

According to reports, "Beta Pharmaceuticals" has established research and development institutions such as "Nobel Prize Research Institute", "Academician Workstation" and "Isotope Labeling Engineering Technology Research Center", and has cooperated with nuclear reactor units, domestic and foreign pharmaceutical and pesticide companies, Cambridge Isotope Laboratory Corporation of the United States, RCTRITECH Corporation of Switzerland, etc. After more than ten years of technical research, it has created five "gold standard" products and technologies in the pharmaceutical and medical fields, it can provide reliable high-tech services for research institutes and enterprise customers. So far, Beta Pharmaceuticals has successfully provided C- 14 tag tracing technology services to dozens of listed companies and leading enterprises in innovative pharmaceutical and pesticide development, such as Hengrui Pharmaceuticals, Hausen Pharmaceuticals, Koren Pharmaceuticals, CSPC, Lier Chemical, Hailer, as well as Shanghai Institute of Pharmaceuticals, Chinese Academy of Sciences, Ecological Environment Research Center, Shenyang Research Institute of Chemical Industry, etc.

Carbon 14 labeled synthesis

None

Focus on isotope technology, beta pharmaceutical research and development to overcome C- 14 labeling key intermediate compounds.

None

Focus on isotope technology, beta pharmaceutical research and development to overcome C- 14 labeling key intermediate compounds.

Promoting the application of carbon -14 isotopes in innovative pharmaceutical development and other fields, "Beta Pharmaceuticals" completed tens of millions of yuan in round B financing.

Beita